Biogen Inc. (BIIB) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 16, 2026
Summary
Biogen’s revenue went from $11.4B in fiscal 2016 to $9.9B in fiscal 2025, a decline of about 1.6% a year.
Net income in fiscal 2025 was $1.3B, a net margin of 13.1%; the best year in this period was 2019 with $5.9B.
Over the twelve months to September 30, 2026, revenue was $10.3B and net income $348M.
Free cash flow was $2.1B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 33% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $10.3B | $9.9B | $9.7B | $9.8B | $10.2B | $11.0B | $13.4B | $14.4B | $13.5B | $12.3B | $11.4B |
| Gross profit | $7.6B | $7.5B | $7.4B | $7.3B | $7.9B | $8.9B | $11.6B | $12.4B | $11.6B | $10.6B | $10.0B |
| Operating income | $750M | $1.6B | $1.9B | $1.3B | $3.6B | $2.8B | $4.6B | $7.0B | $5.9B | $5.3B | $5.2B |
| Net income | $348M | $1.3B | $1.6B | $1.2B | $3.0B | $1.6B | $4.0B | $5.9B | $4.4B | $2.5B | $3.7B |
| EPS (diluted) | $2.32 | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.93 |
| R&D | $2.2B | $1.8B | $2.0B | $2.4B | $2.2B | $2.5B | $4.0B | $2.3B | $2.6B | $2.3B | $2.0B |
| Revenue growth | — | +2.2% | −1.6% | −3.3% | −7.4% | −18.3% | −6.5% | +6.9% | +9.6% | +7.2% | +6.4% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $2.2B | $2.2B | $2.9B | $1.5B | $1.4B | $3.6B | $4.2B | $7.1B | $6.2B | $4.6B | $4.6B |
| Capital spending | -$176M | -$154M | -$154M | -$277M | -$240M | -$258M | -$425M | -$514M | -$771M | -$867M | -$616M |
| Free cash flow | $2.1B | $2.1B | $2.7B | $1.3B | $1.1B | $3.4B | $3.8B | $6.6B | $5.4B | $3.7B | $4.0B |
| Dividends paid | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Buybacks | — | — | $0 | $0 | $750M | $1.8B | $6.7B | $5.9B | $4.4B | $1.4B | $1.0B |
| Stock-based pay | $302M | $291M | $291M | $264M | $254M | $239M | $198M | $182M | $158M | $128M | $155M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $3.8B | $2.4B | $1.0B | $4.9B | $3.8B | $2.6B | $4.5B | $1.2B | $1.6B | $2.3B |
| Debt | — | $6.7B | $6.7B | $7.4B | $6.7B | $9.0B | $8.0B | $8.0B | $6.0B | $5.9B | $6.5B |
| Equity | — | $18.3B | $16.7B | $14.8B | $13.4B | $10.9B | $10.7B | $13.3B | $13.0B | $12.6B | $12.1B |
| Total assets | — | $29.4B | $28.0B | $26.8B | $24.6B | $23.9B | $24.6B | $27.2B | $25.3B | $23.7B | $22.9B |
| Shares (diluted) | 148M | 147M | 146M | 146M | 146M | 150M | 161M | 187M | 205M | 213M | 219M |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 74.0% | 75.7% | 76.1% | 74.2% | 77.6% | 80.8% | 86.6% | 86.4% | 86.5% | 86.7% | 87.1% |
| Operating margin | 7.3% | 15.7% | 19.7% | 13.2% | 35.3% | 25.9% | 33.8% | 49.0% | 43.8% | 43.5% | 45.0% |
| Net margin | 3.4% | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% | 29.8% | 41.0% | 32.9% | 20.7% | 32.3% |
| FCF margin | 20.1% | 20.7% | 28.1% | 12.9% | 11.2% | 30.8% | 28.3% | 45.6% | 40.3% | 30.0% | 34.7% |
| ROIC | — | 5.2% | 7.0% | 5.2% | 14.7% | 13.9% | 19.6% | 27.7% | 23.4% | 15.0% | 20.7% |
| ROE | — | 7.1% | 9.8% | 7.8% | 22.7% | 14.3% | 37.4% | 44.1% | 34.0% | 20.1% | 30.5% |
Frequently asked questions
What is Biogen’s annual revenue?
$9.9B in fiscal 2025 and $10.3B over the twelve months to September 30, 2026.
How much profit does Biogen make?
Net income was $1.3B in fiscal 2025 (net margin 13.1%).
Is Biogen’s revenue growing?
Yes: revenue rose 2.2% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.